Insulet Corporation · NASDAQ:PODD
Insulet — Q4 2022 Earnings Presentation
11 slides from Insulet's earnings presentation, Feb 23, 2023
Slide 1: Insulet Corporation Q4 2022 Earnings
Insulet Corporation Q4 2022 Earnings February 23, 2023 Christian D Podder Since 2020
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains forward-looking statements regarding, among other things, future operating and financial performance, product success and efficacy, the outcome of studies and trials and the approval of products by regulatory bodies. These forward-looking statemen
Slide 3: Non-GAAP Financial Measures
Non-GAAP Financial Measures The Company uses the following non-GAAP financial measures: • Constant currency revenue growth, which represents the change in revenue between current and prior year periods using the exchange rate in effect during the applicable prior year period. Insulet presents consta
Slide 4: Recent Highlights
Recent Highlights Highlights • Recent milestone of ~360,000 estimated active global customers, including over 100,000 using Omnipod 5 • 7th consecutive year of 20% or more constant currency1 revenue growth • Record quarterly and annual U.S. and global Omnipod new customer starts • Newsweek recognize
Slide 5: Strategic Highlights
Strategic Highlights Grant H Morgan M Alecia B Podder Since 2022 Podder Since 2009 Podder Since 2017 Expand Access & Awareness International Innovation & Clinical • Strong Omnipod customer base growth, including • Building cloud-based infrastructure to deliver the • Submitted 510(k) for basal-only P
Slide 6: Financial Performance
Financial Performance Total Revenue & Growth Rates1 U.S. Omnipod Revenue and Growth Rates1 Adjusted Gross Profit and Margin2 Int'l Omnipod Revenue and Growth Rates1 Adjusted Operating Income & Margin2 Total Omnipod Revenue & Growth Rates1 1. Growth rates are on a year-over-year basis and for 2020 th
Slide 7: Key Commercial Metrics- Q4 2022
Key Commercial Metrics- Q4 2022 Omnipod 5 U.S. Covered Lives ~65% 15-20% of U.S. New of U.S. New Starts were MDI Starts were Type 2 U.S. New Customer Starts By Product ~80% Stable of U.S. Volume Global Attrition through and Utilization Pharmacy Trends Note: All commercial metrics are directional est
Slide 8: Product Development Status- Q4 2022
Product Development Status- Q4 2022 Legend Innovation Pipeline U.S. Commercialized Regulatory Product International Submission Development Classic Omnipod Omnipod DASH Omnipod 5 Full market release CE Mark September 2022; w/ G6 August 2022 On track for mid-2023 launch Basal-Only Data products Pod 51
Slide 9: Guidance Highlights - 2023
Guidance Highlights - 2023 FY 2023 Q1 2023 FY 2023 FY 2023 Revenue Growth1 Revenue Growth1 Gross Margin Operating Margin High-Single 14% to 19% 11% to 14% 65% to 66% Digits U.S. Omnipod U.S. Omnipod Expect 2H'23 to be closer to Expect 2H'23 to be higher than 21% to 26% 33% to 36% the high end of ran
Slide 10: Revenue Guidance Reconciliation
Revenue Guidance Reconciliation FY 2023 Q1 2023 Revenue Growth Currency Revenue Growth Currency GAAP Impact Constant Currency GAAP Impact Constant Currency U.S. Omnipod 21% to 26% —% 21% to 26% 33% to 36% —% 33% to 36% International Omnipod 7% to 11% 1% 6% to 10% (2)% to 1% (6)% 4% to 7% Total Omnip
Slide 11: Reconciliation of Non-GAAP Measures
Reconciliation of Non-GAAP Measures % of % of % of % of % of FY2020 Revenue FY2021 Revenue FY2022 Revenue Q4 2021 Revenue Q4 2022 Revenue Total Revenue GAAP Growth Rate 22.5% 21.5% 18.8% 25.0% 20.1% Less: Currency Impact 0.6% 1.8% (3.7)% (0.7)% (3.6)% Constant Currency 21.9% 19.7% 22.5% 25.7% 23.7%